PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsAsparaginase
Elspar, Spectrila(asparaginase)
Elspar, Spectrila (asparaginase) is an enzyme pharmaceutical. Asparaginase was first approved as Elspar on 1978-01-10. It is used to treat cholelithiasis, lymphoma, and precursor cell lymphoblastic leukemia-lymphoma in the USA. It has been approved in Europe to treat precursor cell lymphoblastic leukemia-lymphoma.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
digestive system diseasesD004066
hemic and lymphatic diseasesD006425
immune system diseasesD007154
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Asparaginase
Tradename
Proper name
Company
Number
Date
Products
ElsparasparaginaseRecordatiN-101063 DISCN1978-01-10
1 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
erwinaseunapproved drug for use in drug shortage2021-06-15
rylazeBiologic Licensing Application2025-07-01
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
lymphoma—D008223C85.9
precursor cell lymphoblastic leukemia-lymphoma—D054198C91.0
cholelithiasisEFO_0004799D002769K80
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01X: Other antineoplastic agents in atc
— L01XX: Other antineoplastic agents in atc
— L01XX02: Asparaginase
HCPCS
Code
Description
J9019
Injection, asparaginase (erwinaze), 1,000 iu
J9020
Injection, asparaginase, not otherwise specified, 10,000 units
J9021
Injection, asparaginase, recombinant, (rylaze), 0.1 mg
Clinical
Clinical Trials
315 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Precursor cell lymphoblastic leukemia-lymphomaD054198—C91.0131——4
LeukemiaD007938—C95121——3
Lymphoid leukemiaD007945—C91121——3
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Precursor t-cell lymphoblastic leukemia-lymphomaD054218———1———1
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameAsparaginase
INNcrisantaspase
Description
Asparaginase is an enzyme that is used as a medication and in food manufacturing. As a medication, L-asparaginase is used to treat acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL). It is given by injection into a vein, muscle, or under the skin. A pegylated version is also available. In food manufacturing it is used to decrease acrylamide.
Classification
Enzyme
Drug classenzymes
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB1AGX, 1APY, 1APZ, 1AYY, 1DJO, 1DJP, 1HFJ, 1HFK, 1HFW, 1HG0, 1HG1, 1HO3, 1IHD, 1JAZ, 1JJA, 1JN9, 1JSL, 1JSR, 1K2X, 1NNS, 1O7J, 1P4K, 1P4V, 1T3M, 1WLS, 1WNF, 1WSA, 1ZCF, 2GAC, 2GAW, 2GEZ, 2GL9, 2GVN, 2HIM, 2HLN, 2JK0, 2OCD, 2P2D, 2P2N, 2WLT, 2WT4, 2ZAK, 2ZAL, 3B7C, 3C17, 3ECA, 3LJQ, 3NTX, 3NXK, 3PGA, 3TKJ, 4ECA, 4ET0, 4NJE, 4O0C, 4O0D, 4O0E, 4O0F, 4O0G, 4O0H, 4O47, 4O48, 4OSX, 4OSY, 4PGA, 4PU6, 4PV2, 4PV3, 4PVP, 4PVQ, 4PVR, 4PVS, 4Q0M, 4R4Y, 4R8K, 4R8L, 4RA6, 4RA9, 4ZM9, 5B5U, 5B74, 5CBP, 5DNC, 5DND, 5DNE, 5F52, 5HW0, 5I3Z, 5I48, 5I4B, 5K3O, 5K45, 5K4G, 5K4H, 5MQ5, 5OT0, 5V2I, 6EOK, 6NQ6, 6NX6, 6NX7, 6NX8, 6NX9, 6NXA, 6NXB, 6NXC, 6NXD, 6PA2, 6PA3, 6PA4, 6PA5, 6PA6, 6PA8, 6PA9, 6PAA, 6PAB, 6PAC, 6PAE, 6RUD, 6RUE, 6RUF, 6SYH, 6UOD, 6UOG, 6UOH, 6V23, 6V24, 6V25, 6V26, 6V27, 6V28, 6V29, 6V2A, 6V2B, 6V2C, 6V2G, 6V5F, 6WYW, 6WYX, 6WYY, 6WYZ, 6WZ4, 6WZ6, 6WZ8, 7A0U, 7C8Q, 7C8X, 7C91, 7CB4, 7CBR, 7CBU, 7CBW, 7M11, 7OS3, 7OS5, 7OS6, 7OU1, 7OZ6, 7P9C, 7QQ8, 7QSF, 7QTC, 7QVR, 7QY6, 7QYM, 7QYX, 7R1G, 7R57, 7R5C, 7R5Q, 7R69, 7R6A, 7R6B, 7U6M, 8BI3, 8BKF, 8BP9, 8BQO, 8C0I, 8C23, 8CLY, 8CLZ, 8COL, 8DQM, 8ECD, 8ECE, 8H44, 8H45, 8H46, 8H47, 8H48, 8H49, 8H4A, 8H4B, 8H4C, 8H4D, 8H4E, 8H4F, 8H4G, 8ORI, 8OSW, 8WGQ, 9GAA, 9GAC, 9GAF
CAS-ID9015-68-3
RxCUI1156
ChEMBL IDCHEMBL2108989
ChEBI ID—
PubChem CID—
DrugBankDB00023
UNII IDD733ET3F9O (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Rylaze – Ligand Pharmaceuticals
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Rylaze – Jazz Pharmaceuticals
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 9,999 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
11,626 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use